Showing 7461-7470 of 8825 results for "".
- Garnier Nutrisse Announces Drew Barrymore as Brand Ambassadorhttps://practicaldermatology.com/news/garnier-nutrisse-announces-drew-barrymore-as-brand-ambassador/2461577/Drew Barrymore is the new brand ambassador for Garnier Nutrisse, an expansion to her current role with the Garnier portfolio. Barrymore's role debuts with a creative campaign highlighting Garnier Nutrisse's new and improved Nourishing Color Crème formula for nourished hai
- Incyte Receives Positive CHMP Opinion for Opzelura Cream for the Treatment of Non-Segmental Vitiligohttps://practicaldermatology.com/news/incyte-receives-positive-chmp-opinion-for-opzelura-cream-for-the-treatment-of-non-segmental-vitiligo/2461576/The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
- ASA Renews Support of SPOTS Programhttps://practicaldermatology.com/news/asa-renews-support-of-spots-program/2461565/The American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detectio
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- Escient Pharmaceuticals Receives FDA IND Clearance to Start Phase 1 Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-receives-fda-ind-clearance-to-start-phase-1-study-of-ep262/2461542/The FDA has cleared Escient Pharmaceuticals’ investigational new drug (IND) application for EP262. The clearance allows the Escient to initiate a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development. EP262 is a first-i
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Sirnaomics Accelerates Clinical Development of STP705 for isSCC, BCChttps://practicaldermatology.com/news/sirnaomics-accelerates-clinical-development-of-stp705-for-isscc-bcc/2461535/Sirnaomics Ltd. is advancing the clinical development of STP705 for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formul
- Merz Aesthetics, NWSL’s North Carolina Courage Expand Partnershiphttps://practicaldermatology.com/news/merz-aesthetics-partners-with-wsls-north-carolina-courage-to-fuel-confidence-on-and-off-field/2461532/Merz Aesthetics is expanding its sponsorship of the North Carolina Courage, two-time champions of the National Women’s Soccer League (NWSL). “This partnership is so meaningful for us at Merz Aesthetics,” says Patrick Urban, North America President, in